FDA endorses 10 more medicines for VAT exemption

The Food and Drug Administration (FDA) has endorsed 10 additional drug products for inclusion in the Bureau of Internal Revenue's (BIR) list of Value-Added Tax (VAT)-exempt medicines.

- By Ellalyn De Vera-Ruiz

In FDA Advisory No. 2025-0510 issued on June 4, the agency identified the newly endorsed products, which include treatments for high cholesterol, cancer, diabetes, hypertension, and mental health disorders.

FDA said these conditions are among the leading public health concerns in the country and often require long-term treatment.